A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Regenxbio, Inc.
Start Date
August 2, 2024
End Date
July 14, 2029
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Regenxbio, Inc.
Start Date
August 2, 2024
End Date
July 14, 2029